

FIG. 1A






FIG. 1B

**FIG._2A**

**FIG. 2B**




FIG._3A






FIG._3B

```

                                40          50          60          70
wtIGF      SSRRA-----PQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
            . *  . .          .  *** . . **      *  *  . **  **
proin-     GSLQPLALEGSLQKRGIVEQCCTSICSLYQLENYCN
sulin
            60          70          80
            *** . . **      *  *  . **  **
insulin
            GIVEQCCTSICSLYQLENYCN
(A chain)   31          40          50

```

FIG. 4

**FIG._5A****FIG._5B**

7 / 12




FIG._5C




FIG._5D

1003410-121901




FIG._6A




FIG._6B

9 / 12




FIG. 7




FIG. 11

RESULTS OF IGF-I KIRA ANALYSES OF
PHAGE-GENERATED IGF-I MUTANTS




FIG._8B

RESULTS OF IGF-I KIRA ANALYSES OF
PHAGE-GENERATED IGF-I MUTANTS






FIG._8A

**FIG._9A****FIG._9B**

105121 01422001

+

12 / 12




FIG._10A




FIG._10B

+